COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study

GENCOV is a prospective, observational cohort study of COVID-19-positive adults. Here, we characterize and compare side effects between COVID-19 vaccines and determine whether reactogenicity is exacerbated by prior SARS-CoV-2 infection. Participants were recruited across Ontario, Canada. Participant...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2024-04, Vol.42 (11), p.2733-2739
Main Authors: Morgan, Gregory, Casalino, Selina, Chowdhary, Sunakshi, Frangione, Erika, Fung, Chun Yiu Jordan, Lapadula, Elisa, Arnoldo, Saranya, Bearss, Erin, Binnie, Alexandra, Borgundvaag, Bjug, Briollais, Laurent, Dagher, Marc, Devine, Luke, Friedman, Steven M, Khan, Zeeshan, Mighton, Chloe, Nirmalanathan, Konika, Richardson, David, Stern, Seth, Taher, Ahmed, Wolday, Dawit, Lerner-Ellis, Jordan, Taher, Jennifer
Format: Article
Language:English
Subjects:
Adult
COVID-19
COVID-19 - prevention & control
COVID-19 vaccines
COVID-19 Vaccines - adverse effects
Ethnicity
Fever
Headaches
Hospitals
Humans
Immunization
Infections
Medical research
mRNA
mRNA vaccines
Observational studies
Ontario - epidemiology
Pain
Prospective Studies
Questionnaires
Reactogenicity
Regression analysis
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Side effects
Vaccine safety
Vaccines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:GENCOV is a prospective, observational cohort study of COVID-19-positive adults. Here, we characterize and compare side effects between COVID-19 vaccines and determine whether reactogenicity is exacerbated by prior SARS-CoV-2 infection. Participants were recruited across Ontario, Canada. Participant-reported demographic and COVID-19 vaccination data were collected using a questionnaire. Multivariable logistic regression was performed to assess whether vaccine manufacturer, type, and previous SARS-CoV-2 infection are associated with reactogenicity. Responses were obtained from n = 554 participants. Tiredness and localized side effects were the most common reactions across vaccine doses. For most participants, side effects occurred and subsided within 1–2 days. Recipients of Moderna mRNA and AstraZeneca vector vaccines reported reactions more frequently compared to recipients of a Pfizer-BioNTech mRNA vaccine. Previous SARS-CoV-2 infection was independently associated with developing side effects. We provide evidence of relatively mild and short-lived reactions reported by participants who have received approved COVID-19 vaccines.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2024.03.030